GlaxoSmithKline Pharmaceuticals Limited has scheduled a board meeting on May 13, 2026. The board will consider audited standalone and consolidated financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window remains closed until May 16, 2026.
GlaxoSmithKline Pharmaceuticals Limited has scheduled a Board Meeting on May 13, 2026. The directors will consider and approve the audited standalone and consolidated financial results for the year ended March 31, 2026. The board will also consider recommending a dividend on equity shares for the period.